T cell-directed anti-aging and anti-cancer vaccines against commensal cytomegalovirus
AssigneeThe General Hospital Corporation
InventorsShadmehr Demehri, Tatsuya Hasegawa
Life of this patent
Estimating the term…
Abstract
Immune-based approaches to reduce the risk of, delay the onset of, and/or slow the progression of aging and aging-associated diseases by boosting T cell immunity against commensal human cytomegalovirus (HCMV).
Claims32
A method of delaying the onset or slowing progression of aging in a subject, the method comprising administering to the subject an effective amount of a composition comprising:
- a plurality of (i) antigenic proteins from commensal human cytomegaloviruses (HCMV), (ii) antigenic peptides derived from proteins from commensal human cytomegaloviruses, or (iii) live or live-attenuated commensal human cytomegaloviruses;
- and
- a T cell adjuvant that increases T cell response to the plurality of the antigenic proteins, the antigenic peptides, or the live or live-attenuated commensal human cytomegaloviruses.
A method of reducing the level of senescent fibroblasts in a subject, the method comprising administering to the subject an effective amount of a composition comprising:
- a plurality of (i) antigenic proteins from commensal human cytomegaloviruses (HCMV), (ii) antigenic peptides derived from proteins from commensal human cytomegaloviruses, or (iii) live or live-attenuated commensal human cytomegaloviruses;
- and
- a T cell adjuvant that increases T cell response to the plurality of the antigenic proteins, the antigenic peptides, or the live or live-attenuated commensal human cytomegaloviruses.
A method of treating, or reducing the risk of developing, an aging-associated disease or condition in a subject, the method comprising administering to the subject an effective amount of a composition comprising:
- a plurality of (i) antigenic proteins from commensal human cytomegaloviruses (HCMV), (ii) antigenic peptides derived from proteins from commensal human cytomegaloviruses, or (iii) live or live-attenuated commensal human cytomegaloviruses;
- and
- a T cell adjuvant that increases T cell response to plurality of the antigenic proteins, the antigenic peptides, or the live or live-attenuated commensal human cytomegaloviruses.
A composition comprising:
- 90 a plurality of (i) antigenic proteins from commensal human cytomegaloviruses (HCMV), (ii) antigenic peptides derived from proteins from commensal human cytomegaloviruses, or (iii) live or live-attenuated commensal human cytomegaloviruses;
- and
- a T cell adjuvant that increases T cell response to the plurality of the antigenic 95 proteins, the antigenic peptides, or the live or live-attenuated commensal human cytomegaloviruses, for use in a method of treating, or reducing the risk of developing, an aging-associated disease or condition in a subject.
Dependencies are inferred from the claim text.